JP2023505543A5 - - Google Patents
Info
- Publication number
- JP2023505543A5 JP2023505543A5 JP2022534860A JP2022534860A JP2023505543A5 JP 2023505543 A5 JP2023505543 A5 JP 2023505543A5 JP 2022534860 A JP2022534860 A JP 2022534860A JP 2022534860 A JP2022534860 A JP 2022534860A JP 2023505543 A5 JP2023505543 A5 JP 2023505543A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945412P | 2019-12-09 | 2019-12-09 | |
| US62/945,412 | 2019-12-09 | ||
| US202062982305P | 2020-02-27 | 2020-02-27 | |
| US62/982,305 | 2020-02-27 | ||
| PCT/IB2020/061582 WO2021116872A1 (en) | 2019-12-09 | 2020-12-07 | Pharmaceutical compositions comprising cabotegravir |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023505543A JP2023505543A (ja) | 2023-02-09 |
| JP2023505543A5 true JP2023505543A5 (https=) | 2023-12-15 |
| JPWO2021116872A5 JPWO2021116872A5 (https=) | 2023-12-15 |
| JP7703538B2 JP7703538B2 (ja) | 2025-07-07 |
Family
ID=73834567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534860A Active JP7703538B2 (ja) | 2019-12-09 | 2020-12-07 | カボテグラビルを含んでなる医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230045509A1 (https=) |
| EP (1) | EP4072520B1 (https=) |
| JP (1) | JP7703538B2 (https=) |
| KR (1) | KR20220112771A (https=) |
| CN (1) | CN114786648A (https=) |
| AU (1) | AU2020402659A1 (https=) |
| BR (1) | BR112022010574A2 (https=) |
| CA (1) | CA3164528A1 (https=) |
| ES (1) | ES3051362T3 (https=) |
| IL (1) | IL293566A (https=) |
| MX (1) | MX2022006940A (https=) |
| TW (1) | TW202135815A (https=) |
| UY (1) | UY38982A (https=) |
| WO (1) | WO2021116872A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2025068743A1 (en) * | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| US11718637B2 (en) * | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| CN115397424A (zh) * | 2020-04-15 | 2022-11-25 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
| WO2022051198A1 (en) | 2020-09-01 | 2022-03-10 | Viiv Healthcare Company | Combination of cabotegravir and levonorgestrel |
| US20250296988A1 (en) * | 2020-12-07 | 2025-09-25 | Viiv Healthcare Company | Combination therapy |
| CA3241017A1 (en) * | 2021-12-17 | 2023-06-22 | Robert Ferris | Combination therapies for hiv infections and uses thereof |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121909019A (zh) | 2023-09-27 | 2026-04-21 | Viiv保健英国第三有限公司 | 药物组合物 |
| WO2025128498A1 (en) * | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Pharmaceutical compositions |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202602442A (zh) | 2024-03-01 | 2026-01-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 | 給藥方案 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550155B2 (en) * | 2002-07-29 | 2009-06-23 | Transform Pharmaceuticals Inc. | Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses |
| US8129385B2 (en) | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| US20170165271A1 (en) * | 2014-02-24 | 2017-06-15 | The Board Of Regents Of The University Of Nebraska | Compositions and Methods for the Delivery of Therapeutics |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| SI3129392T1 (sl) * | 2014-04-11 | 2020-11-30 | VIIV Healthcare UK(No.4) Limited | Triterpenoidi z inhibitorno aktivnostjo maturacije HIV-a, substituirani na položaju 3 z nearomatskim obročem, ki nosi haloalkilni substituent |
| US10092523B2 (en) * | 2014-09-26 | 2018-10-09 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| CN109195633A (zh) * | 2016-02-12 | 2019-01-11 | 西普拉有限公司 | 包含抗逆转录病毒药物和药代动力学增效剂的药物组合物 |
| EP4299133A3 (en) * | 2016-06-23 | 2024-03-13 | VIIV Healthcare Company | Compositions and methods for the delivery of therapeutics |
| WO2018002902A1 (en) * | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| ES2970042T3 (es) * | 2018-04-24 | 2024-05-24 | Viiv Healthcare Uk No 5 Ltd | Compuestos con actividad inhibidora de la maduración del VIH |
| CN120053445A (zh) * | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| WO2020112931A1 (en) * | 2018-11-29 | 2020-06-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| AU2020231934B2 (en) * | 2019-03-06 | 2023-04-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in HIV therapy |
| EP3962603A1 (en) * | 2019-04-30 | 2022-03-09 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| LT3986561T (lt) * | 2019-06-19 | 2024-04-25 | VIIV Healthcare UK (No.5) Limited | Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai |
| PE20221037A1 (es) * | 2019-09-11 | 2022-06-17 | Scripps Research Inst | Profarmacos antivirales y composiciones farmaceuticas de los mismos |
-
2020
- 2020-12-07 UY UY0001038982A patent/UY38982A/es not_active Application Discontinuation
- 2020-12-07 TW TW109143111A patent/TW202135815A/zh unknown
- 2020-12-07 IL IL293566A patent/IL293566A/en unknown
- 2020-12-07 WO PCT/IB2020/061582 patent/WO2021116872A1/en not_active Ceased
- 2020-12-07 AU AU2020402659A patent/AU2020402659A1/en not_active Abandoned
- 2020-12-07 CN CN202080085115.9A patent/CN114786648A/zh active Pending
- 2020-12-07 CA CA3164528A patent/CA3164528A1/en active Pending
- 2020-12-07 BR BR112022010574A patent/BR112022010574A2/pt not_active Application Discontinuation
- 2020-12-07 KR KR1020227018750A patent/KR20220112771A/ko not_active Withdrawn
- 2020-12-07 MX MX2022006940A patent/MX2022006940A/es unknown
- 2020-12-07 JP JP2022534860A patent/JP7703538B2/ja active Active
- 2020-12-07 US US17/756,971 patent/US20230045509A1/en active Pending
- 2020-12-07 EP EP20824345.1A patent/EP4072520B1/en active Active
- 2020-12-07 ES ES20824345T patent/ES3051362T3/es active Active